Burosumab: Mechanism, Uses & Side Effects
Burosumab is a monoclonal antibody used to treat X-linked hypophosphatemia. It inhibits FGF23 and helps restore normal phosphate levels in the blood.
Things worth knowing about "Burosumab"
Burosumab is a monoclonal antibody used to treat X-linked hypophosphatemia. It inhibits FGF23 and helps restore normal phosphate levels in the blood.
What is Burosumab?
Burosumab is a fully human monoclonal antibody approved for the treatment of X-linked hypophosphatemia (XLH), a rare inherited disorder in which the body cannot maintain adequate phosphate levels in the blood. This leads to rickets, bone deformities, impaired growth in children, and chronic musculoskeletal pain in adults. Burosumab is marketed under the brand name Crysvita and is approved for both children and adults.
Indications
Burosumab is approved for:
- X-linked hypophosphatemia (XLH) in children aged one year and older and in adults
- Tumor-induced osteomalacia (TIO) in adults where the causative tumor cannot be completely resected or localized
Mechanism of Action
In XLH and TIO, the protein FGF23 (Fibroblast Growth Factor 23) is excessively elevated in the bloodstream. Under normal conditions, FGF23 plays a role in regulating phosphate excretion by the kidneys. When FGF23 levels are too high, the kidneys excrete too much phosphate in the urine (hyperphosphaturia), leading to chronically low blood phosphate levels (hypophosphatemia) and impaired vitamin D activation.
Burosumab binds directly and selectively to FGF23, blocking its biological activity. This results in:
- Increased phosphate reabsorption in the kidneys
- Normalization of serum phosphate levels
- Increased activation of vitamin D (to 1,25-dihydroxyvitamin D)
- Improved bone mineralization and healing of rickets or osteomalacia
Dosage and Administration
Burosumab is administered as a subcutaneous injection (under the skin). The dose is based on body weight and serum phosphate levels:
- Children (XLH): Typically every 2 weeks, starting dose of 0.4 mg/kg body weight
- Adults (XLH): Typically every 4 weeks, starting dose of 1.0 mg/kg body weight
- Adults (TIO): Dosing adjusted individually based on phosphate levels, given every 2 or 4 weeks
The dose is regularly adjusted to maintain serum phosphate within the target range. Concomitant use of oral phosphate supplements or active vitamin D analogues should be avoided during burosumab therapy, as this increases the risk of hyperphosphatemia and nephrocalcinosis.
Side Effects
Burosumab is generally well tolerated. The most commonly reported side effects include:
- Injection site reactions (redness, swelling, pain)
- Headache
- Dizziness
- Tooth pain or dental abscesses
- Elevated blood phosphate levels (hyperphosphatemia)
- Vitamin D imbalance
- Rash or itching
In rare cases, ectopic mineralization (unwanted calcium deposits in soft tissues or kidneys) may occur. Regular laboratory monitoring is therefore required throughout the course of treatment.
Treatment Context and Clinical Significance
Before burosumab became available, the standard treatment for XLH consisted of high-dose oral phosphate supplements combined with active vitamin D analogues (calcitriol or alfacalcidol). This regimen was associated with significant side effects, including diarrhea, nephrocalcinosis, and secondary hyperparathyroidism. Burosumab, by contrast, targets the underlying disease mechanism directly and has demonstrated superior efficacy in clinical trials, including improved healing of rickets, reduction in bone pain, and better physical function.
Burosumab is classified as a biologic therapy and belongs to the monoclonal antibody drug class. It was developed by Kyowa Kirin and received approval from the European Medicines Agency (EMA) in 2018.
References
- European Medicines Agency (EMA): Crysvita (Burosumab) - European Public Assessment Report (EPAR), 2018. Available at: https://www.ema.europa.eu
- Insogna KL et al. - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab in Adults with XLH. Journal of Bone and Mineral Research, 2018.
- Carpenter TO et al. - Burosumab Therapy in Children with X-Linked Hypophosphatemia. New England Journal of Medicine, 2018; 378(21): 1987-1998.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryAbemaciclib
Bictegravir
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Burosumab